CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Pharmacyte Biotech Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Pharmacyte Biotech Inc
3960 Howard Hughes Parkway, Suite 500
Phone: (917) 595-2850p:917 595-2850 LAS VEGAS, NV  89169  United States Ticker: PMCBPMCB
Business Summary
PharmaCyte Biotech, Inc. is a biotechnology company. It is focused on developing cellular therapies for cancer, diabetes, and malignant ascites based upon a cellulose-based live cell encapsulation technology known as Cell-in-a-Box. Its product candidate is referred to as CypCaps. The Cell-in-a-Box encapsulation technology potentially enables genetically engineered live human cells to be used to produce various biologically active molecules. It is advancing clinical research and development of new cellular-based therapies in oncology and diabetes. It is also focused on developing therapies for pancreatic and other solid cancerous tumors by using genetically engineered live human cells. Its product candidate for the treatment of diabetes consists of encapsulated genetically modified insulin-producing cells. It is also focused on the benefits of the Cell-in-a-Box technology to develop therapies for cancer that involve prodrugs based upon certain constituents of the Cannabis plant.
(Source: F-4)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
1/31/20244/30/2023YesYes--Yes

Industries
SIC Code Description
2833 Medicinal chemicals and botanical products
2879 Pesticides and agricultural chemicals, not elsewhere classified
8731 Commercial physical and biological research
2834 Pharmaceutical preparations

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Interim Chairman of the Board, Interim President, Interim Chief Executive Officer Joshua N.Silverman 53 10/6/2022 8/15/2022
Chief Financial Officer, Director Carlos A.Trujillo 65 3/1/2017 3/1/2017
Director RobertWeinstein 63 11/14/2022 11/14/2022
3 additional Officers and Directors records available in full report.

Business Names
Business Name
PharmaCyte Biotech Australia Pty. Ltd.
PharmaCyte Biotech Europe Limited
PMCB
PMCBD
Viridis Biotech, Inc.

General Information
Number of Employees: 2 (As of 4/30/2023)
Outstanding Shares: 8,453,396 (As of 3/20/2024)
Shareholders: 1,400
Stock Exchange: NASD
Federal Tax Id: 621772151
Fax Number: (917) 595-2851
Email Address: info@nuvilex.com


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Thursday, April 18, 2024